Andao Pharmaceutical
安道药业
Andao Pharmaceutical is a Hangzhou-based biotech developing small-molecule drugs, with its lead asset AND017 in clinical trials for kidney disease and cancer-related anemia. The company raised a $50 million Series B in late 2021 co-led by Gaorong Ventures and Northern Light Venture Capital, with additional backing from Decheng Capital, Ancheng Capital, and Yingfeng Capital . As of 2022 reporting, Nobel laureate Gregg L. Semenza served as chair of its scientific advisory board, and founder Liu Dong held the chairman and CEO roles . Gaorong Ventures, which has tracked the firm across multiple "Rongbao" portfolio updates, later participated in a further funding round .
AI-generated — may contain errors, please verify.
Coverage
Andon Therapeutics Raises Over 400 Million Yuan in Series C Funding to Accelerate Phase III Clinical Trials for Revolutionary Pan-Anemia Drug
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
高榕创投·From Big Pharma to Biotech: Four Industry Leaders on How Innovative Drugs Can Balance Speed and Quality | Ronghui
Speed matters, but getting it right matters more.
高榕创投·Robotics, SaaS, and innovative drug sectors close new funding rounds; chips and medical devices unveil major new products | Rongbao · August
Differentiated innovation and global opportunities.
高榕创投·Robots, AI, and Simulation Technologies Accelerate Industrial Adoption | Rongbao · June
Technology drives industrial transformation.
高榕创投·Chips, Energy Storage, and LiDAR Accelerate Commercialization; Robotics and SaaS Expand Globally | Rongbao · May
Sailing through the waves, striving upstream.
高榕创投·Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
高榕创投·
